Abbvie Inc
NYSE:ABBV
Abbvie Inc
Total Current Assets
Abbvie Inc
Total Current Assets Peer Comparison
Competitive Total Current Assets Analysis
Latest Figures & CAGR of Competitors
Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$33B
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
6%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$16.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$30.3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
Moderna Inc
NASDAQ:MRNA
|
Total Current Assets
$10.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$14.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
30%
|
CAGR 10-Years
24%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$19.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
25%
|
CAGR 10-Years
27%
|
See Also
What is Abbvie Inc's Total Current Assets?
Total Current Assets
33B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Total Current Assets amounts to 33B USD.
What is Abbvie Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
6%
Over the last year, the Total Current Assets growth was 16%. The average annual Total Current Assets growth rates for Abbvie Inc have been 11% over the past three years , 14% over the past five years , and 6% over the past ten years .